Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | +1.72% | -1.66% | +10.96% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
Business Summary
Number of employees: 181
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cellular Immunotherapies
100.0
%
| 96 | 100.0 % | 64 | 100.0 % | -34.03% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 96 | 100.0 % | 64 | 100.0 % | -34.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
Chairman | 76 | 11-10-31 | |
Wen Bo Wang
CTO | Chief Tech/Sci/R&D Officer | - | 18-10-07 |
Bahram Valamehr
CTO | Chief Tech/Sci/R&D Officer | 47 | 18-07-31 |
Jerome C. Bressi
LAW | General Counsel | - | 18-11-30 |
Cindy Tahl
LAW | General Counsel | 51 | 08-12-31 |
Jim Beitel
PRN | Corporate Officer/Principal | - | 17-09-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
Chairman | 76 | 11-10-31 | |
John Mendlein
FOU | Founder | 64 | 07-04-26 |
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Michael Lee
BRD | Director/Board Member | 45 | 18-07-30 |
Karin Jooss
BRD | Director/Board Member | 59 | 19-03-13 |
Shefali Agarwal
BRD | Director/Board Member | 50 | 19-07-14 |
Yuan Xu
BRD | Director/Board Member | 56 | 21-08-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 113,831,969 | 112,032,716 ( 98.42 %) | 0 | 98.42 % |
Stock B | 0 | 2,761,108 | 0 | 0 |
Company contact information
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
92131, San Diego
+858 875 1800
http://www.fatetherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.96% | 472M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.30% | 21.93B | |
-12.15% | 22.34B | |
-5.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- FATE Stock
- Company Fate Therapeutics, Inc.